Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464164 | 0.94 | PDE1A (0.46) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL4460628 | 0.87 | PDE1A (0.48) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL4472695 | 0.79 | PDE1A (0.56) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL4469992 | 0.76 | PDE1A (0.59) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL4475016 | 0.74 | SMN1; SMN2 (0.52) | ADORA2B | |
| SCHEMBL11386065 | 0.70 | PDE1A (0.60) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL4558878 | 0.70 | PDE1A (0.54) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL7089727 | 0.68 | ADORA2B (0.68) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL11385374 | 0.67 | PDE1A (0.56) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL9853395 | 0.67 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550468-B2 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | CHEN ING-JUN | 2009-06-23 | — | — | US | disclosed |
| US-20050209242-A1 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | CHEN ING-JUN | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209242-A1 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | PDE3A, PDE5A, PDE3B | PDE4A 7/4885PDE4B 9/4885PDE4C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.